Patents, Drug Delivery and Public Health Protection: Health Risk Management for Nanopharmaceuticals by Sant`Anna, Leonardo da Silva et al.
107
ISSN: 0718-2724. (http://www.jotmi.org) 
Journal of Technology Management & Innovation © Universidad Alberto Hurtado, Facultad de Economía y Negocios.
J. Technol. Manag. Innov. 2013, Volume 8, Issue 2Received November 27, 2012 / Accepted April 24, 2013
I State University of Rio de Janeiro (UERJ). Address: Rua São Francisco Xavier, 524, Maracanã - Cep: 20550-013, +55 21 25877100, lsan-
tanna44@gmail.com. Associate Professor at Faculty of Lawn in State University of Rio de Janeiro, Rio de Janeiro, Brazil.
1, 2 Study Centre of Workers’ Health and Human Ecology (CESTEH). Address: Rua Leopoldo Bulhões, 1480, Manguinhos - Cep: 21041-210, 
+55 21 25982814, aldopachecoferreira@gmail.com. Researcher at Sérgio Arouca National School of Public Health, Study Centre of Work-
ers’ Health and Human Ecology, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
3 Institute of Scientific and Technological Communication and Information in Health (ICICT). Address: Avenida Brasil, 4365, Manguinhos 
- Cep: 21040-900, +55 21 38829167, salencar@gmail.com. Researcher at Institute of Scientific and Technological Communication and In-
formation, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Patents, Drug Delivery and Public Health Protection: Health Risk 
Management for Nanopharmaceuticals 
Leonardo da Silva Sant’AnnaI,  Aldo Pacheco Ferreira2, Maria Simone de Menezes Alencar3
Abstract
The present article discusses the general risks associated with nanotechnology applications and the deficits of the risk 
management of engineered nanopharmaceutical particles. An evaluation of the possible health or environmental risks 
of nanoparticles must systematically be carried out and it is important to ensure that particle size and chemistry are 
taken into account when investigating possible adverse effects. It has been a goal subsidizes the policy-makers to adapt 
and modernize the regulatory framework on nanotechnology and risks involving health as a strategic area in the politics 
of Science. It is essential that health and environment be always directly or indirectly involved in various researches 
to understand the causes of affections and to develop control procedures in order to avoid them, providing results 
achievable, reliable and secure.
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sessments are also valuable when quantitative assessments 
are not possible (Montague, 2004). Even under the best of 
circumstances, risk assessment cannot estimate risk with ab-
solute certainty. Modern quantitative risk assessment aims 
not to arrive at a single precise number, but to allow deci-
sion makers to face the possible consequences of a range 
of not undoubtedly incorrect responses and elect on the 
protective policies that are acceptable in light of the range 
of possible future outcomes of substitute policies (Cattaneo, 
et al., 2010; Bottini, et al., 2011). Thus, if there is uncertainty 
regarding exposures or dose in a population, one can ei-
ther collect more data or use numerical models to estimate 
missing values or extrapolate values from other analogous 
populations (Fadeel and Garcia-Bennett, 2010).
Uncertainties about the health effects directly feed the 
risk-benefit discussions that increasingly make emergency 
responses for the regulation of new technologies (Choi, 
et al., 2009; Allarakhia and Wash, 2012). Although some 
applications of nanotechnology in pharmacology may be 
questioned, there is an area where the application of na-
notechnology application is promising (Davies, 2006; Fadeel 
and Garcia-Bennett, 2010). Specifically, nanoformulations 
may eliminate the need for conditional administration of 
drugs, thereby promoting patient compliance and increas-
ing therapeutic effects (Dorbeck-Jung, et al., 2011). However, 
like biotechnology before it, concerns about environmental 
and human health risks have already begun to have an effect 
on the societal debate around nanotechnology. Suspicions 
about risks of nanotechnology result from a basic enigma: 
the properties that make nanoparticles so promising, that 
they can perform very differently from bulk forms of the 
same material, and also make their health and environmen-
tal effects extremely difficult to predict (Ju-Nam and Lead, 
2008). Some of the nanophamaceutical-based formulations 
are listed in Table I.
Nanoparticle risks posture a new form of risk assessment 
challenge. Besides a lack of data, there is deep scientific 
uncertainty regarding every aspect of the risk assessment 
framework: (a) particle characteristics that may affect toxic-
ity; (b) their fate and transport through the environment; (c) 
the routes of exposure and the metrics by which exposure 
ought to be measured; (d) the mechanisms of translocation 
to different parts of the body; and (e) the mechanisms of 
toxicity and disease (Althaus, 2005; Borm, et al., 2006; Cat-
taneo, et al., 2010). In each of these areas, there are multiple 
and competing models and hypotheses.
Traditional risk assessment
Risk assessment is a complex process that involves the in-
tegration of information across a range of domains includ-
ing source characterization, fate and transport, modelling, 
Introduction
Hesitations in conventional quantitative risk assessment 
characteristically relate to values of parameters in risk mod-
els. For various environmental pollutants, there is a lack of 
appropriate information about multiple components of the 
risk valuation framework (Althaus, 2005; Borm, et al., 2006). 
In such cases, the use of default assumptions and extrapola-
tions to fill in the data gaps is a common practice (Pidgeon, 
et al., 2011).
Nanoscience is characterized as the product of interdisci-
plinary collaboration among biotechnology, chemistry, phys-
ics, material sciences and engineering toward studying as-
sociations of atoms and molecules (Schulte, 2005; Salerno, 
et al., 2008). More than in other domains, nanotechnology 
requires the integration of many scientific, engineering and 
technical disciplines and competences (Antunes, et al., 2012; 
Pyrrho and Schramm, 2012). Applications of nanotechnology 
will penetrate nearly all sectors and spheres of life and will 
be accompanied by changes in the social, economic, ethical 
and ecological spheres (Schummer, 2004; Zanetti-Ramos and 
Creczynski-Pasa, 2008).
Nanotechnology refers to the development and application 
of materials, devices and systems with fundamentally new 
properties and functions because of their structures in the 
range of about 1-100 nanometres (Meyer and Persson, 1998; 
Cameron, 2006). It involves the manipulation and/or crea-
tion of material structures at the nanoscale, in the atomic, 
molecular and supramolecular realm (Schulte, 2005). Com-
monly these nanoparticles are natural products but their 
great commercial use has improved the artificial synthesis 
of these engineered nanoparticles (Lanone and Boczkowski, 
2006; Mccomas and Besley, 2011). Accelerated production 
and use of these nanoparticles may cause their discharge 
in the environment and enable the frequent contacts with 
biotic and abiotic components of the ecosystems (Brar, et 
al., 2010). Regardless of notable commercial profits, their 
presences in the nature can origin harmful biological special 
effects. Consequently, detail understanding of their sources, 
relief contact with environment, and probable risk assess-
ment would provide a basis for nontoxic use of engineered 
nanoparticles with negligible or no dangerous influence on 
environment (Kuempel, et al., 2012).
The human health impact of toxic substances and pollutants 
can be studied using frameworks of risk assessment devel-
oped over the past decades. Risk assessment in this context 
is a set of tools used to integrate exposure and health ef-
fect information for characterizing the potential for health 
hazards to humans (Marchant and Sylvester, 2006; Mccomas 
and Besley, 2011). Such methods typically use quantitative 
expectations of health impacts. However, qualitative risk as-
Product Company Drug Application
Doxil Sequus Pharmaceu-tical Doxorubicin Kaposi sarcoma in AIDS
Amphocil Sequus Pharmaceu-tical Amphotericin B Serious fungal infections
Ambisome NeXstar Pharmaceu-tical Amphotericin B Serious fungal infections
DaunoXome NeXstar Pharmaceu-tical
Daunorubicin 
citrate Kaposi sarcoma in AIDS
Abelcet The Liposome Com-pany Amphotericin B Serious fungal infections
Rapamune Wyeth/Elan Sirolimus Immunosuppressant in kidney transplant patients
Emend Merck/Elan Aprepitant, MK869
For chemotherapy patient to delayed nau-
sea and vomiting
TriCor Abbott Fenofibrate Primary hypercholesterolemiamixed lipidemia, hypertriglyceridemia
Megace ES PAR Pharmaceu-tical
Megaestrol ac-
etate
Treatment of anorexia, cachexia, or an unexplained 
significant weight loss in patients with a diagnosis 
of AIDS
Abraxane American Biosci-ences Paclitaxel Metastatic breast cancer
Elestrin BioSante Estradiol
Treatment of moderate-to-severe vasomotor 
symptoms (hot flashes) in menopausal wom-
en
109
ISSN: 0718-2724. (http://www.jotmi.org) 
Journal of Technology Management & Innovation © Universidad Alberto Hurtado, Facultad de Economía y Negocios.
J. Technol. Manag. Innov. 2012, Volume 8, Issue 2
Table I. Some selected nanopharmaceutical products currently on the market.
exposure assessment, and dose–response characteristics 
(Mccomas and Besley, 2011; Pyrrho and Schramm, 2012). It 
uses well-defined quantitative models to describe the re-
lationships between the various elements of the paradigm 
shown in Figure I explaining the general environmental 
health framework and its relationship to the risk assessment 
framework.
Exposure is defined as the intensity of contact between con-
taminant and the relevant biological sites of impact over a 
relevant time period (Siegrist and Keller, 2011). Exposure as-
sessment includes assessing sources of pollutants and their 
strengths, measuring or modelling concentrations in envi-
ronmental media, measuring or modelling human exposures 
through various pathways, and in some cases even biological 
monitoring to measure tissue burden and thereby estimate 
dose. The estimation of a biologically relevant dose from ex-
posure information is, however, often very difficult and re-
quires fairly detailed knowledge of the toxicokinetics of the 
pollutant in the human body (Shah and Khan, 2009; Pautler 
and Brenner, 2010).
Risk governance are important concepts for assessing and 
managing the implications of nanotechnology which looks 
set to become the next focus for heated debate about the 
relationship between new technologies, risk and sustain-
ability (Dorbeck-Jung, et al., 2011). It includes the totality 
of actors, rules, conventions, processes, and mechanisms 
concerned with how relevant risk information is collected, 
analysed and communicated and management decisions are 
taken (Kosta and Bowman, 2010). Risk governance includes 
the processes, conventions and institutions that determine, 
some important questions, like as: How power is exercised 
in view of managing resources and interests? How impor-
tant decisions are made and conflicts resolved? How various 
stakeholders are accorded participation in these processes?
The flowchart in Figure 2 suggests that the main steps in the 
research and regulation of nanomaterial implications once 
released either in the environment or at the working place. 
The implications affect biosphere, surrounding infrastruc-
ture, and public health. The risk governance should ensure 
safety and the dynamic behaviour and multifunctionality of 
the nanostructure. The main argument is that nanotechnolo-
gy represents a new class of processes and applications that 
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Figure I. General environmental health framework for risk assessment.
may threaten human identity; speed up the pace of moderni-
zation beyond the speed that human societies can cope with; 
and transform our environment into directions that nobody 
can realistically predict.
Translocation and health effect endpoints
A critical difference between nanoparticles and particles of 
larger size is the ability to nanoparticles to move or trans-
locate to different parts of the body (Rediguieri, 2009; Kosta 
and Bowman, 2010). There is evidence for the translocation 
of inhaled nanoparticles from the alveolar spaces into the 
interstitial, to local and regional lymph nodes, and into the 
circulatory system.
Translocation into the blood stream may also affect the abili-
ty of blood to coagulate (Robinson, 2009). There is consider-
able uncertainty regarding the extent of translocation, which 
may depend on the surface and chemical characteristics of 
the particles. More recently, a growing body of evidence sug-
gests that nanoparticles may translocate along the neuronal 
pathways into the central nervous system and the brain 
(Rossi-Bergmann, 2008). However, the exact mechanisms of 
transport have not been elucidated and there may yet be 
other pathways in addition to neuronal transport.
The small size facilitates uptake into cells and transport 
across epithelial and endothelial cells into the blood and 
lymph circulation, which may carry nanoparticles to po-
tentially sensitive target sites such as bone marrow, lymph 
nodes, spleen, and heart (Youns, et al., 2011). The ability to 
reach new regions, unhindered by natural blocking mecha-
nisms of the body is, not surprisingly, the reason that nano-
particles may be useful in medical applications.
The fate and transport of larger particles is well understood 
and inhalation is the exposure route (Schulte, 2005; Salerno, 
et al., 2008). The preceding discussion shows that for nano-
particles, several exposures routes are possible. This is sum-
marized in Figure 3, which illustrates that there are several 
pathways and potential endpoints for assessing the adverse 
health effects of nanoparticles in the body. In the case of 
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Methodology
Initially an interdisciplinary analysis was executed to establish the 
type of therapeutic pertinent class, based on information of the 
Brazilian Sanitary Surveillance Agency (ANVISA). The therapeu-
tic uses qualified in accordance with the Anatomical Therapeutic 
Chemical Classification System (ATC), which is controlled by 
the WHO Collaborating Centre for Drug Statistics Methodol-
ogy (WHOCC). This task demanded a considerable effort and 
included searches in international databases, since, in many cases, 
the released information was not indicating the generic name 
of the respective product or his possible therapeutic application.
To collect data on patents in Brazil was used the Brazilian Na-
tional Institute of Industrial Property (INPI) database for the 
period of patent applications filed from 1991 to 2011. Our ap-
proach to developing a nanotechnology bibliometric search in-
volved these steps: It was used a quantitative approach based on 
a bibliometric analysis of data obtained at the base of INPI. Data 
were collected within the last Electronic Journal of Industrial 
Property (EJIP) (INPI/2011), using 18 terms related to nano-
technology. In addition to the terms proposed by INPI, others 
were included, based on articles that deal with search strategies 
or bibliometrics analyses on nanotechnology (Coatrieux, et al., 
2004; Porter and Cunningham, 2005; Daim, et al., 2006; He and 
Loh, 2010; Wang, et al., 2012). The terms were truncated in or-
der to optimize and maximize results and are as follows: Den-
drimer*, Nanod*, Nanom*, Fio* Quantic*, Nanoe*, Nanonet*, 
Fuleren*, Nanof*, Nanop*, Grafen*, Nanog*, Nanos*, Nanoh*, 
Nanob*, Nanot*, Nanoc*, Nanoi*, and Ponto* Quantic* (Feld-
man and Sanger, 2007).
inhalation, larger particulates are deposited in the lungs and 
can cause localized health effects within the pulmonary sys-
tem (Davies, 2006; Fadeel and Garcia-Bennett, 2010).
Nanoparticles, on the other hand, could have multiple health 
endpoints (Ju-Nam and Lead, 2008). For example, inhaled 
nanoparticles might translocate to the central nervous sys-
tem either through neural pathways in the olfactory system 
or through the body’s circulatory systems after absorption 
in the lungs and consequent crossing of the blood-brain 
barrier (Lanone and Boczkowski, 2006). The ability of na-
noparticles to translocate to parts of the body that are not 
accessible to larger particles in the particulate matter range 
or to most toxic chemicals and carcinogens make it harder 
to extrapolate known laboratory and epidemiological find-
ings to nanoparticles. In other words, existing physiological 
models of exposure and movement of particles within the 
human body are not sufficient.
Keeping all these points in mind and after identifying the 
main characteristics and prospects of nanotechnology as 
an emerging technology upon various aspects, e.g. sources, 
different types, synthesis, interaction with environment, the 
present article discuss the general risks associated with na-
notechnology applications and the deficits of the risk gov-
ernance process today, aiming propose recommendations of 
possible strategies for risk management of engineered nano-
pharmaceutical particles, in detach to governments, industry, 
national organizations and other stakeholders.
Figure 2. Risk governance and policies for active nanostructures and nanosystems.
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Results
Profile of the Brazilian Pharmaceutical Patents
Most of the patents granted (116, 31.69 %) belongs to com-
panies that possess his counterfoil in the United States. Sec-
ondly it belongs to Brazilian companies, with a participation 
of 27.87 %. The remaining percentage (40.44 %) is distrib-
uted in 23 countries, which go from 7.97 % to 0.27 %, being 
demonstrated appears in the Table 2.
The main result of the research was to generate a data-
base of pharmaceutical patents granted, one of whose main 
purposes is to provide information for decision-making, par-
ticularly in relation to products and ways to acquire more 
efficient procurement. This database yielded the results de-
scribed below. In Figure 4 is demonstrated an analysis com-
paring quantitative data of pharmaceutical patents with na-
notechnology patents observed from 1990 to 2011.
It was evaluated the typology of depositors, detaching in per-
centage: (a) legal entity non-resident; (b) legal entity resident; 
(c) individual non-resident; (d) individual resident; (e) Scien-
tific & Technologic Institution non-resident; and (f) Scientific 
& Technologic Institution resident, as showed in Figure 5. It´s 
observed that, for the period studied (1990-2011), 85% of 
Nanotechnologic patents deposited and 59.5% of Pharma-
ceuticals patents are related to legal entity non-resident in 
To make this survey were selected patent documents (pat-
ents, utility models and certificates of addition to invention), 
containing in its title and / or abstract, at least one of the 
18 terms listed above. Utility models were also included 
because they are susceptible for industrial application, and 
certificates of addition which are complementary inventions 
ever made, were also included in the study, totaling 1352 
patent applications.
As data regarding to the legal process, the following fields 
were collected: (i) filing date, (ii) application title given by 
the inventor to his invention, (iii) name of the depository – 
patent holder or organization, (iv) notification - stage of the 
patenting process, (v) EJIP issue which published the notifi-
cation, (vi) date of EJIP publication, (vii) applicant’s country 
origin, and (viii) IPC main application. It was evaluated the 
typology of depositors, detaching their peculiarities: (a) legal 
entity non-resident; (b) legal entity resident; (c) individual 
non-resident; (d) individual resident; (e) Scientific & Techno-
logic Institution non-resident; and (f) Scientific & Technologic 
Institution resident.
For patent mining, in analysis of observational data sets to 
find unsuspected relationships and to summarize the data 
in novel ways that are both understandable and useful, as 
well as to generate reports for analyzing the results in more 
consistently manner, was used the automated data mining 
tool, the software VantagePoint 7.1, Search Technology, Inc.
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Table 2. Relative participation pharmaceuticals patents deposited in the period of 1990-2011, according to intellectual author.
Nationality Quantity of Patents Percentage


























Figure 4. Comparative quantitative data of pharmaceutical and nanotechnology patents, according to the study period (1990-2011)
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environmental science community also needs to embrace 
this positive approach, and devise appropriate testing proto-
cols and predictive tools for addressing the crucial issue of 
risk management.
Another interesting point to be noted is that some nano-
particles have identical or similar chemical formula to an 
existing compound. This results in another by-pass of nano-
particles from chemical abstracting service which provides a 
series of unique identifying numbers for existing chemicals. 
Other than these non-specific rules, not only there are no 
specific regulations for nanoparticles, but also, the gaps in 
knowledge regarding their toxicological and exposure data 
prevail (Mcintyre, 2012). It is therefore an important matter 
of concern to build up specific legislations and guidelines for 
nanoparticles in order to avoid the risk imposed by nano-
particles on the environment.
Considering the wide application of nanoparticles and their 
entry into the environment, the study of their impact on 
the ecosystem, at biotic as well as abiotic level, has become 
mandatory (Paschoalino, et al., 2010). Only a limited num-
ber of areas have been covered as far as ecotoxicity tests 
and assessment of the hazardous effects of nanoparticles are 
concerned. Therefore, it is required to study their release, 
uptake, and mode of toxicity in the organisms. Furthermore, 
to understand the long-term effect of nanoparticles on the 
ecosystem, substantial information is required regarding 
their persistence and bioaccumulation. But it is a reasonably 
good surrogate that large-scale epidemiological studies have 
yielded remarkably consistent results (Rickerby, 2007).
Brazil, in sequence it were found, 21% and 6.5% for legal 
entity resident, 5% and 4% for individual depositor non-res-
ident, 23% and 6.6% for individual depositor resident, 8.5% 
and 6.6% for depositor from Scientific and Technologic In-
stitutions non-resident, and a promising result of 42.5% and 
12% for depositor from Scientific and Technologic Institu-
tions resident.
Discussion
Due to serious environmental and health risk posed by the 
release of nanoparticles in the environment, it becomes es-
sential to set specific standards for the manufacture, use, 
and disposal of nanoparticles (Choi, et al., 2009). There are 
many fail reports about legislations do not mention or de-
fine nanoparticles (Chamas, 2008). However, a number of 
organizations have evolved development, description and 
usage-associated standards for nanoparticles. The potential 
hazard by nanoparticles and the subsequent protection of 
environment and human health should consider these stand-
ards. Therefore, some nanoparticles by-pass the testing and 
safety evaluations as their concentration seldom reach this 
limit. 
Nanotechnology holds out the promise of immense im-
provements in economic growth, health and manufacturing 
technologies; and especially pharmaceuticals products (Fer-
nandes and Filgueiras, 2008). Both the nanotechnology in-
dustries and governments are now seriously considering the 
possibility of unforeseen risks for human health and environ-
mental degradation as a result of this novel technology. The 
Figure 5. Distribution of pharmaceutical and nanotechnology patents deposited in Brazil by typology (1990-2011).
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rently taxing the ability of the regulatory system to provide 
adequate oversight. Uncertainties of definition, absence of 
a tracking system, and the scarcity of scientific evidence to 
support risk management efforts are among the findings of 
the study and need to be addressed as ameliorative steps 
toward an effective regulatory structure.
In many situations, there is a lack of sufficient information 
about multiple components of this risk framework. In such 
cases, agencies such as the United States Environmental Pro-
tection Agency (U.S.EPA) have resorted to the use of default 
assumptions and extrapolations to fill in the data gaps. In 
the case of nanoparticle health risks the uncertainties are 
so large as to obviate any simple extrapolations. Meanwhile, 
the technology is moving at a rapid pace, new nanoparticles 
are routinely manufactured and the social costs of getting 
it wrong are very high. In such a situation, there is a need 
for quantitative frameworks that help in risk assessment and 
expert judgment may be a valuable tool for doing this.
Health risks from nanoparticles share some features of risk 
calculations. The fundamental mechanisms for health risks 
from nanoparticles are largely unknown and extreme un-
certainty prevails in almost every aspect of the exposure–
response paradigm. No epidemiological data are available 
for engineered nanoparticle exposures, and it is unlikely that 
such data will be available in the near future in the absence 
of scientific consensus on the proper exposure metric and 
relevant health effect to be measured. This way, while com-
prehensive risk evaluation is far from feasible, even simple 
screening assessments are difficult due to the novelty of the 
materials and the lack of basic toxicity data. 
Globally, healthcare costs have been increasing due to the 
costs associated with healthcare development in a heav-
ily regulated environment and higher patient expectations. 
Cost-effective technologies and cutting-edge treatments, 
seeking early minimal intervention rather than invasive ther-
apies, are therefore mandatory. Nanomedicine as a trans-
lational science has the goal to offer cost effective novel 
therapies and diagnostics using the expanding world of na-
notechnology. To reach this goal the process of translating 
research results from academic laboratories to the clinic has 
becoming greatly enhanced.
Concerning nanomedication we can say that there is no suf-
ficient consensus among the different actors that lets end 
the controversy, and this disagreement involves not only the 
discussions are subsidized by the interests of manufactur-
ing new products, however they should be permeated be-
tween science, risk concerns, and public health. Otherwise, 
nanomedicine is currently a major scientific controversy, and 
there is no way of knowing when and how this controversy 
will end, but the fact is that in trying to build something 
Indeed, the development of new molecules for pharmaceuti-
cal application may involve several levels of inventive tech-
niques for the preparation of drugs in different forms and 
dosages are usually known (Poirot-Mazeres, 2011). There-
fore, there is a limited range may be considered develop-
ments in this field genuinely inventive. The patent examiner 
should pay particular attention to the following cases of 
claims: (i) Formulations, compositions and processes for 
their preparation should be considered obvious in view of 
prior art, except in those cases in which obtaining a truly un-
expected and surprising effect; (ii) Combinations: the com-
binations of known active ingredients should be regarded as 
devoid of inventiveness, with the exception of those cases 
where it is clearly established a new synergistic effect that 
is not obvious; (iii) Dosages / dose: the new dose for the 
same indication or for a different indication not constitute 
invention, particularly in countries like Brazil, where treat-
ment methods are not patentable; (iv) Salts, ethers and es-
ters, the salts, esters and other known pharmaceutical forms 
can generally be obtained through common procedures, and 
are not patentable, except in those cases where this is an 
unexpected advantage over the prior art; (v) Polymorphs: 
the polymorphism is an inherent property of matter in its 
solid state, the polymorphs not invention but are discovered 
as-they are not patentable as such. Moreover, the patenting 
of procedures for polymorphs should be considered only in 
cases that actually meets the requirements of novelty and 
inventive step; (vi) Individual enantiomers: patentable not be 
considered when the racemic mixture is disclosed (but it 
may be patentable processes for obtaining individual enan-
tiomers, are novel and possess if inventive step); (vii) Active 
metabolites: patentable should not be considered separately 
from the active ingredient derived; (viii) Prodrugs: if granted, 
patents on prodrugs should be excluded from the claim to 
the active substance itself, if it has already been reported 
or is not patentable; (ix) Selections: the selection of a single 
item or small segment within a larger group known as the 
selected components have already been revealed, should not 
be patentable even if there are unexpected benefits; and (x) 
Procedures like: manufacturing procedures that are not in 
themselves novel and inventive to be considered unpatent-
able, beyond which the starting materials, intermediates and 
the final product is novel or inventive.
Conclusion
Innovative technologies and their resultant products de-
mand new ways of thinking about pre-market risk analysis 
and post-market surveillance. A regulatory framework that 
is responsive to emerging knowledge about the hazards of 
novel technologies offers repeatable and transparent pro-
cesses and remains economically and socially feasible. Na-
nopharmaceuticals and the nano-based technologies at their 
base are used by way of exemplar technologies that are cur-
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